FDA-approved for medication-refractory movement disorders (e.g. Parkinson's disease, dystonia, essential tremor) and OCD
Being studied for use in epilepsy, chronic pain, depression, PTSD
Single lead systems implanted into the thalamus<unk> rates range from 7-65%
Being studied for use in epilepsy, chronic pain, depression, PTSD
Deep brain stimulator complications
Brain herniation syndromes
Ventriculoperitoneal shunt complications
Vagal nerve stimulator complications
Ventriculoperitoneal shunt overdrainage
Post-lumbar puncture headache
Ventriculoperitoneal shunt mechanical failure
Ventriculoperitoneal shunt infection